~~<i id='3C919C4C45'><strike id='3C919C4C45'><tt id='3C919C4C45'><pre id='3C919C4C45'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

Wikipedia

author：explore 2025-10-02 21:00:39 - browse：23974

Monica Bertagnolli -- health policy coverage from STAT — NIH Director Monica Bertagnolli Kevin Dietsch/Getty Images

WASHINGTON — President Biden has promised to require fair prices from drugmakers that use federally funded research — and now, in a major recent move, said he’ll trigger government “march-in” on patents for drugs that run afoul of that goal.

“It’s a simple principle. You shouldn’t pay the highest price in the world for drugs that your tax dollars have already helped create,” Biden said last month as he touted the move at the National Institutes of Health.

But the new NIH director, locked in the center of this debate, isn’t taking any big steps yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

explore

focus

knowledge

focus

hotspot

MarkWilson/NewsmakersWhentheWhiteHousereleasedPresidentBiden’s2025budgetrequeststhisweek,fundingforb

WSS

New documents shed light on MD Anderson Cancer Institute feud

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Community Health Systems hospitals under DOJ investigation

Alabama IVF ruling threatens families facing fatal genetic disease

How many hemophilia patients actually want gene therapy?

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

explore

Wikipedia

explore

Jerome Adams on the need for new antivirals for Covid

John Green on his newest strategy for fighting tuberculosis

Hepatitis C has a cure — but many Americans still lack access to it

Why scientists need input from humanists on sensitive research

DIEP, the 'gold standard' of breast reconstruction, is under threat

First U.S. drug developed to treat liver disease MASH is approved

Walensky prepares to leave CDC — and Congress — behind

Steward Health Care Massachusetts hospitals face fiscal disaster

As demand for Covid shots wanes, Moderna seeks its next success

Ebola: Gilead Sciences antiviral shows promise as new treatment

explore

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

A solution to the after

As AI in medicine takes off, can 'human in the loop' prevent harm?

Alabama hospital puts IVF treatments on hold

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

focus

knowledge

focus

hotspot